文献速递头颈与中枢神经肿瘤胸部肿瘤骨软组织肉瘤与黑色素瘤

德国放射肿瘤学调查:实体瘤放疗/放化疗与免疫检查点抑制剂联合治疗的临床研究现状

State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours-a German radiation oncology survey.
PubMed 文献 · Eur J Cancer · 2019-01-12

该调查面向德国放射肿瘤学会及青年DEGRO成员,评估实体瘤放疗/放化疗与免疫检查点抑制剂(ICI)联合研究的现状。应答来自14家德国大学医院放疗科,61%的受访者在本机构开展联合研究并参与多中心研究,联合治疗主要在东颈部肿瘤(95%)、肺癌(57%)、恶性黑色素瘤(48%)和上消化道肿瘤(9%)中探索。超过85%的受访者认为联合治疗有效或非常有效,61%认为对颅内转移性疾病非常有效。调查显示新联合治疗模式接受度高,超过75%的中心正在开展相关研究。

要点

  • 联合治疗研究主要在东颈部肿瘤(95%)、肺癌(57%)、恶性黑色素瘤(48%)中开展。
  • 超过85%的受访者认为放疗/放化疗联合ICI有效或非常有效。
  • 61%的受访者认为该联合方案对颅内转移性疾病非常有效。

核心结论

  • 调查显示新型联合治疗模式接受度高,ICI联合放疗和/或放化疗在超过75%的参与中心正在开展研究。
  • 东颈部肿瘤、非小细胞肺癌(NSCLC)和恶性黑色素瘤是最常被测试的肿瘤类型。

研究设计与样本

  • 向德国放射肿瘤学会及青年DEGRO成员发放调查问卷,应答来自14家德国大学医院放疗科。
  • 对同一科室的应答者进行一致性分析。

主要发现

  • 61%的受访者在本机构开展放疗/放化疗与ICI联合治疗研究并参与多中心研究。
  • 联合治疗研究主要在东颈部肿瘤(95%)、肺癌(57%)、恶性黑色素瘤(48%)和上消化道肿瘤(9%)中开展。
  • 放化疗与检查点抑制剂联合仅在东颈部肿瘤(52%)、非小细胞肺癌(NSCLC)(8.70%)和恶性黑色素瘤(4%)中测试。
  • 超过85%的受访者认为放疗/放化疗联合ICI有效或非常有效。
  • 61%的受访者认为该联合方案对颅内转移性疾病非常有效。

关键数值与推荐

  • 联合治疗研究主要在东颈部肿瘤(95%)、肺癌(57%)、恶性黑色素瘤(48%)和上消化道肿瘤(9%)中开展。
  • 放化疗与检查点抑制剂联合仅在东颈部肿瘤(52%)、非小细胞肺癌(NSCLC)(8.70%)和恶性黑色素瘤(4%)中测试。
  • 超过85%的受访者认为放疗/放化疗联合ICI有效或非常有效。
  • 61%的受访者认为该联合方案对颅内转移性疾病非常有效。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Combinations of immune checkpoint inhibitors (ICIs) with radiotherapy and/or chemoradiotherapy are currently under investigation in many cancer types and clinical settings. In this survey, we solicited members of the German Radiation Oncology Society and young DEGRO (working group of DEGRO e.V.) to review the current status of research in this field and underline critical issues such as oncological benefit, treatment toxicity and obstacles in clinical research. The responses represent 14 different departments of radiation oncology at German university hospitals. Respondents of the same department were analysed for congruence. Sixty-one percent of all respondents perform radiotherapy/chemoradiotherapy and ICI therapy combination studies at their institutions and participate in multicentre studies. Combinations were investigated mainly in head and neck tumours (95%), lung cancer (57%), malignant melanoma (48%) and tumours of the upper gastrointestinal tract (9%). Combination of chemoradiotherapy with checkpoint inhibitors was only tested in head and neck cancers (52%), non-small-cell lung cancer (NSCLC) (8.70%) and malignant melanoma (4%). A combination of radiotherapy/chemoradiotherapy with ICIs is assumed to be effective or very effective by >85% of all respondents. The treatment of intracranial metastatic disease by this combination is assumed to be very effective by most respondents (61%). The present survey shows great acceptance of new combined modality treatment paradigm. ICIs with radiotherapy and/or chemoradiotherapy are under investigation at >75% of all participating centres. Head and neck tumours, NSCLC and malignant melanoma are the most frequently tested cancer types.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Käsmann L, Eze C, Dantes M, et al. State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours-a German radiation oncology survey. Eur J Cancer. 2019. PMID: 30648629. doi:10.1016/j.ejca.2018.11.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。